BridgeMD
Tests treatment safety and results for Plaque Psoriasis
Official title A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov ID: NCT07234591
What this study is testing
What is Tyk2 inhibitor?
Tyk2 inhibitor is an investigational medicine, being studied as a potential treatment for plaque psoriasis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Male and female, ages 18 to 70 years
- Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
- Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
- Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.
You likely can't join if
- Diagnosed with non-plaque psoriasis
- Previously received tyrosine kinase 2 (TYK2) inhibitors
- Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before...
- Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits...
- Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately...
- Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;
See the full eligibility criteria
- Male and female, ages 18 to 70 years
- Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
- Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
- Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.
- Diagnosed with non-plaque psoriasis
- Previously received tyrosine kinase 2 (TYK2) inhibitors
- Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the...
- Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
- Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint...
- Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;
- Other conditions that the investigator deems unsuitable for participation in this study. Other protocol defined inclusion/exclusion criteria could apply
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.